Federal Register Notice: FDA’s Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will meet 6/27, from 8 a.m. to 4 p.m. at the CDER Conference Room, Rm. 1066, 5630 Fishers Lane, Rockville, MD. The subcommittee will (1) Discuss review of oncology products granted pediatric exclusivity under the Best Pharmaceuticals for Children Act (BPCA); and (2) discuss 13-cis retinoic acid: summary of clinical experience, including access through iPledge, and additional clinical studies for the treatment of patients with neuroblastoma to be conducted under the BPCA. Contact Mimi Phan, (301) 827- 7001. To view this notice, click here.